Krezsita 50/1000 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, which regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from alpha cells. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Krezsita 50/1000 is typically administered once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Regular monitoring of renal function, glycemic parameters, and potential adverse effects such as lactic acidosis is recommended during therapy. This combination therapy offers an effective and convenient option for optimizing glycemic control in type 2 diabetes management.